Structural Basis for the Autoinhibition and STI-571 Inhibition of c-Kit Tyrosine Kinase*
暂无分享,去创建一个
K. Wilson | Biching Sang | C. Mol | D. Scheibe | T. Schneider | R. Skene | D. Dougan | G. Snell | Thomas R Schneider | Bi-Ching Sang | Daniel N Scheibe | Keith P Wilson | Hua Zou | Robert J Skene | Clifford D Mol | Douglas R Dougan | Michelle L Kraus | Gyorgy P Snell | M. Kraus | Hua Zou
[1] D. Heitjan,et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] T Pawson,et al. Oncogenic mutation in the Kit receptor tyrosine kinase alters substrate specificity and induces degradation of the protein tyrosine phosphatase SHP-1. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[3] G. Murshudov,et al. Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.
[4] Marius Sudol,et al. The WW domain: linking cell signalling to the membrane cytoskeleton. , 2002, Cellular signalling.
[5] B. Druker,et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. , 2000, The Journal of pharmacology and experimental therapeutics.
[6] R. Pearson,et al. Intrasteric regulation of protein kinases and phosphatases. , 1991, Biochimica et biophysica acta.
[7] C. Heldin,et al. Dimerization of cell surface receptors in signal transduction , 1995, Cell.
[8] T. Schneider. A genetic algorithm for the identification of conformationally invariant regions in protein molecules. , 2002, Acta crystallographica. Section D, Biological crystallography.
[9] Duc Hung Le,et al. SHP-1 Binds and Negatively Modulates the c-Kit Receptor by Interaction with Tyrosine 569 in the c-Kit Juxtamembrane Domain , 1998, Molecular and Cellular Biology.
[10] T. Hunter,et al. NeW Wrinkles for an Old Domain , 2000, Cell.
[11] T. Hunter,et al. Oncogenic kinase signalling , 2001, Nature.
[12] S. Hubbard,et al. Structural and Biochemical Evidence for an Autoinhibitory Role for Tyrosine 984 in the Juxtamembrane Region of the Insulin Receptor* , 2003, Journal of Biological Chemistry.
[13] D E McRee,et al. XtalView/Xfit--A versatile program for manipulating atomic coordinates and electron density. , 1999, Journal of structural biology.
[14] Avijit Chakrabartty,et al. Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region , 2003, Molecular and Cellular Biology.
[15] D. DiMaio,et al. A single amino acid substitution in a WW‐like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation , 1998, The EMBO journal.
[16] Olivier Hermine,et al. Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms , 2003, Oncogene.
[17] L. Regan,et al. Inhibition of Spontaneous Receptor Phosphorylation by Residues in a Putative α-Helix in the KIT Intracellular Juxtamembrane Region* , 1999, The Journal of Biological Chemistry.
[18] Arthur Weiss,et al. Switching Signals On or Off by Receptor Dimerization , 1998, Cell.
[19] S. Hirota,et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene , 1998, Nature Genetics.
[20] S. Hubbard,et al. Crystal structure of the MuSK tyrosine kinase: insights into receptor autoregulation. , 2002, Structure.
[21] T. Pawson,et al. Structural Basis for Autoinhibition of the EphB2 Receptor Tyrosine Kinase by the Unphosphorylated Juxtamembrane Region , 2001, Cell.
[22] D. Linnekin,et al. Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.
[23] C. Moskaluk,et al. Activating c-kit gene mutations in human germ cell tumors. , 1999, The American journal of pathology.
[24] D. Birnbaum,et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. , 1993, Blood.
[25] Inder M. Verma,et al. Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus , 1986, Nature.
[26] J Navaza,et al. Implementation of molecular replacement in AMoRe. , 2001, Acta crystallographica. Section D, Biological crystallography.
[27] Z. Otwinowski,et al. [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[28] Shan Zeng,et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. , 2002, Blood.
[29] S. Hirota,et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. , 1998, Science.
[30] A. Ullrich,et al. Structure of the receptor for platelet-derived growth factor helps define a family of closely related growth factor receptors , 1986, Nature.
[31] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[32] S. Hubbard,et al. Autoregulatory Mechanisms in Protein-tyrosine Kinases* , 1998, The Journal of Biological Chemistry.
[33] S. Hubbard,et al. Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.
[34] D. Cruickshank,et al. Remarks about protein structure precision. , 1999, Acta crystallographica. Section D, Biological crystallography.
[35] F. Lu,et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. , 2004, Molecular cell.
[36] E. Chien,et al. Structure of a c-Kit Product Complex Reveals the Basis for Kinase Transactivation* , 2003, Journal of Biological Chemistry.
[37] S. Hubbard. Protein tyrosine kinases: autoregulation and small-molecule inhibition. , 2002, Current opinion in structural biology.
[38] I. Matsumura,et al. Constitutive Activation of C-kit by the Juxtamembrane but Not the Catalytic Domain Mutations Is Inhibited Selectively by Tyrosine Kinase Inhibitors STI571 and AG1296 , 2002, International journal of hematology.
[39] J. Kuriyan,et al. The Conformational Plasticity of Protein Kinases , 2002, Cell.
[40] Joseph Schlessinger,et al. Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.
[41] Marius Sudol,et al. WW and SH3 domains, two different scaffolds to recognize proline‐rich ligands , 2002, FEBS letters.
[42] D. DiMaio,et al. Definition of an Inhibitory Juxtamembrane WW-like Domain in the Platelet-derived Growth Factor β Receptor* , 2002, The Journal of Biological Chemistry.
[43] C. Heldin,et al. cDNA cloning and expression of the human A-type platelet-derived growth factor (PDGF) receptor establishes structural similarity to the B-type PDGF receptor. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[44] John Kuriyan,et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). , 2001, Cancer research.
[45] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[46] S. Hubbard,et al. Crystal structure of the tyrosine kinase domain of the human insulin receptor , 1994, Nature.
[47] S. Hirota,et al. A loss-of-function mutation of c-kit results in depletion of mast cells and interstitial cells of Cajal, while its gain-of-function mutation results in their oncogenesis. , 2001, Mutation research.
[48] G. Superti-Furga,et al. Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase , 2003, Cell.
[49] John E. Murphy,et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family , 1986, Nature.
[50] Daniel Scheibe,et al. A fully integrated protein crystallization platform for small-molecule drug discovery. , 2003, Journal of structural biology.